Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 7/20 | 0.79 |
| ▸ | PDE5A | O76074 | 6/20 | 0.79 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.79 |
| ▸ | MIF | P14174 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 1/20 | 0.79 |
| ▸ | PDE4A | P27815 | 1/20 | 0.79 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.79 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.79 |
| ▸ | BLM | P54132 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.79 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.79 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10033623 | 1.00 | PDE4B (0.79) | PDE4BPDE5APDE3AMIFMEN1 | |
| SCHEMBL652912 | 1.00 | PDE4B (0.79) | PDE4BPDE5APDE3AMIFMEN1 | |
| Hydrochloric Acid SCHEMBL653339 | 0.99 | PDE4B (0.77) | PDE4BPDE5APDE3AMIFMEN1 | |
| Hydrochloric Acid SCHEMBL652575 | 0.99 | PDE4B (0.77) | PDE4BPDE5APDE3AMIFMEN1 | |
| Ibudilast SCHEMBL4194864 | 0.88 | PDE4B (1.00) | PDE4BPDE5APDE3AMIFMEN1 | |
| Ibudilast SCHEMBL30390 | 0.88 | PDE4B (1.00) | PDE4BPDE5APDE3AMIFMEN1 | |
| SCHEMBL8224246 | 0.87 | PDE4B (0.77) | PDE4BPDE5APDE3AMIFMEN1 | |
| SCHEMBL3203334 | 0.87 | PDE4B (0.81) | PDE4BPDE5APDE3AMIFMEN1 | |
| SCHEMBL3206069 | 0.87 | PDE4B (0.71) | PDE4BPDE5APDE3AMIFMEN1 | |
| SCHEMBL3192986 | 0.87 | PDE4B (0.71) | PDE4BPDE5APDE3AMIFMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377074-B2 | Treatment for Wolfram syndrome | YALE UNIVERSITY (US) | 2025-08-05 | — | — | US | claimed |
| US-20220347159-A1 | NOVEL TREATMENT FOR WOLFRAM SYNDROME | UNIV YALE (US) | 2022-11-03 | — | — | US | claimed |
| EP-2445504-A1 | ENANTIOMERIC COMPOSITIONS OF 2-AMINO-1-(2-ISOPROPYLPYRAZOLO[1,5-a]PYRIDIN-3-YL)PROPAN-1-ONE AND RELATED METHODS | MediciNova, Inc. (US) | 2012-05-02 | — | — | EP | claimed |
| US-8119657-B2 | Enantiomeric compositions of 2-amino-1-(2-isopropylpyrazolo[1,5-α]pyridin-3-yl)propan-1-one and related methods | MEDICINOVA, INC. (US) | 2012-02-21 | — | — | US | claimed |
| WO-2010151551-A1 | ENANTIOMERIC COMPOSITIONS OF 2-AMINO-1-(2-ISOPROPYLPYRAZOLO[1,5-a]PYRIDIN-3-YL)PROPAN-1-ONE AND RELATED METHODS | MEDICINOVA, INC. (US) | 2010-12-29 | — | — | WO | claimed |
| US-20100324082-A1 | ENANTIOMERIC COMPOSITIONS OF 2-AMINO-1-(2-ISOPROPYLPYRAZOLO[1,5-a]PYRIDIN-3-YL)PROPAN-1-ONE AND RELATED METHODS | MEDICINOVA, INC. | 2010-12-23 | — | — | US | claimed |
| US-20100035920-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | AVIGEN, INC. (US) | 2010-02-11 | — | — | US | claimed |
| US-20090318437-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | MEDICINOVA, INC. | 2009-12-24 | — | — | US | claimed |
| US-7585875-B2 | Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use | AVIGEN, INC. (US) | 2009-09-08 | — | — | US | claimed |
| EP-4663249-A2 | DRUG THERAPY TO INHIBIT CHEMOTHERAPY-INDUCED ADVERSE EFFECTS AND RELATED PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING TECHNIQUES AND KITS | Yale University, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12377074-B2 | Treatment for Wolfram syndrome | YALE UNIVERSITY (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4186501-B1 | DRUG THERAPY TO INHIBIT CHEMOTHERAPY-INDUCED ADVERSE EFFECTS AND RELATED PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING TECHNIQUES AND KITS | YALE UNIV INC (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-3740205-B1 | METHODS OF SUPPRESSING MYELOID-DERIVED SUPPRESSOR CELLS IN PATIENTS | MEDICINOVA INC (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20230201254-A1 | DRUG THERAPY TO INHIBIT CHEMOTHERAPY-INDUCED ADVERSE EFFECTS AND RELATED PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING TECHNIQUES AND KITS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-06-29 | — | — | US | disclosed |
| US-7585875-B2 | Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use | AVIGEN, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585875-B2 | Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use | AVIGEN, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585875-B2 | Substituted pyrazolo[1,5-a]pyridine compounds and their methods of use | AVIGEN, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-20080070912-A1 | Substituted pyrazolo [1,5-a] pyridine compounds and their methods of use | AVIGEN, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080070912-A1 | Substituted pyrazolo [1,5-a] pyridine compounds and their methods of use | AVIGEN, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2007146087-A2 | SUBSTITUTED PYRAZOLO [1,5-α] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | AVIGEN, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377074-B2 | Treatment for Wolfram syndrome | WFS1, NLN, TNNI3 | PDE4B 1264/4885PDE5A 1688/4885PDE3A 1448/4885 |
| US-20090318437-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | PNPO, PDXK, CYP3A5 | PDE4B 383/4885PDE5A 418/4885PDE3A 620/4885 |
| US-20100324082-A1 | ENANTIOMERIC COMPOSITIONS OF 2-AMINO-1-(2-ISOPROPYLPYRAZOLO[1,5-a]PYRIDIN-3-YL)PROPAN-1-ONE AND RELATED METHODS | OPRK1, OPRL1, OPRD1 | PDE4B 2121/4885PDE5A 2327/4885PDE3A 629/4885 |
| US-20080070912-A1 | Substituted pyrazolo [1,5-a] pyridine compounds and their methods of use | PNPO, PDXK, P2RX5 | PDE4B 351/4885PDE5A 413/4885PDE3A 557/4885 |
| US-20220347159-A1 | NOVEL TREATMENT FOR WOLFRAM SYNDROME | WFS1, TNNI3, TWF2 | PDE4B 1069/4885PDE5A 1845/4885PDE3A 2171/4885 |
| US-20100035920-A1 | SUBSTITUTED PYRAZOLO[1,5-a] PYRIDINE COMPOUNDS AND THEIR METHODS OF USE | PNPO, PDXK, CYP3A5 | PDE4B 383/4885PDE5A 418/4885PDE3A 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.